STEADY-PD III. A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson's disease. Study design and status update

Category Primary study
ConferenceMovement Disorders
Year 2015
This article has no abstract
Epistemonikos ID: 4a0eda9a315222570daebb505a50b85a4ba13e22
First added on: Apr 30, 2026